SCHEDULE: Soleus Capital Discloses 5% Stake in Vericel Corp

Soleus Capital Master Fund and related entities have reported a 5.0% passive beneficial ownership in Vericel Corp's common stock.

Summary

• Soleus Capital Master Fund, L.P., along with its affiliated entities Soleus Capital, LLC, Soleus Capital Group, LLC, Soleus Capital Management, L.P., Soleus GP, LLC, and Guy Levy, have filed a Schedule 13G.
• The reporting group collectively beneficially owns 2,549,079 shares of Vericel Corp's common stock.
• This ownership represents 5.0% of Vericel Corp's total outstanding common stock.
• The percentage is calculated based on 50,763,319 shares of Vericel Corp common stock outstanding as of February 19, 2026, as reported in Vericel's Annual Report on Form 10-K.
• The filing certifies that the shares were not acquired and are not held for the purpose of changing or influencing the control of Vericel Corp, indicating a passive investment.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as a significant institutional investor has taken a substantial passive stake, suggesting a belief in Vericel Corp's value proposition.

Positives

• A significant institutional investor, Soleus Capital, has taken a 5.0% stake in Vericel Corp, which can be interpreted as a vote of confidence in the company's long-term prospects and valuation.

Future Outlook

This filing, a Schedule 13G, does not contain any forward-looking statements or guidance from Vericel Corp. It solely reports the beneficial ownership of a passive investor group.

Management Comments

• "The securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

StockSavvy.ai notes that a 5% passive stake by an investment fund like Soleus Capital in a company such as Vericel Corp, which operates in the biotechnology or medical technology sector, often signals a belief in the company's underlying value or future growth prospects without seeking active management involvement. Such filings are a routine disclosure for institutional investors reaching the 5% ownership threshold.

Comparison to Industry Standards

• A 5% passive stake is a standard threshold for Schedule 13G filings, indicating a significant but non-controlling investment, consistent with typical institutional investor behavior.
• This type of investment is comparable to other institutional investors taking strategic, non-activist positions in publicly traded companies within the healthcare or biotech space, focusing on long-term value appreciation rather than immediate operational changes.

Stakeholder Impact

• Shareholders: May view the institutional investment as a vote of confidence, potentially leading to increased investor interest and positive sentiment.
• Management: Awareness of a significant passive shareholder, though without direct influence on operations or strategic decisions.

Next Steps

• Soleus Capital and its related entities will continue to monitor their investment in Vericel Corp.
• Further Schedule 13G/A amendments would be filed if there are material changes to their ownership percentage or investment intent.

Key Dates

Recommendation

The disclosure of a 5.0% passive stake by Soleus Capital Master Fund and its affiliates in Vericel Corp indicates institutional confidence in the company. While this is a positive signal, the filing itself does not provide new operational or financial data about Vericel Corp to warrant a stronger recommendation than 'hold' for existing investors, or to initiate a 'buy' without further due diligence on Vericel's fundamentals. It suggests the stock is worth holding given the institutional interest.

Keywords

Vericel Corp, Soleus Capital, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investment, Passive Stake, SEC Filing, 92346J108